. Author manuscript; available in PMC: 2009 Nov 26.

Published in final edited form as: Vasc Dis Prev. 2008 Aug 1;5(3):200–210. doi: 10.2174/156727008785133809

Table 1.

Lipodomic Profile of Basal and C₆-Ceramide-Treated Human Coronary Artery Smooth Muscle Cells and Human Coronary Artery Endothelial Cells

Treatment	Cell Type	Total Ceramide (pmol/mg protein)	C-1-P (pmol/mg protein)	Cerebrosides (pmol/mg protein)
Vehicle	HCASMC	382.4 ± 28.5	5.87 ± 0.95	330.50 ± 44.02
Vehicle	HCAEC	270.6 ± 17.2	4.55 ± 0.88	*19.68* ± 4.20
C₆-Ceramide	HCASMC	8207.8 ± 438.8	9.02 ± 1.30	4070.30 ± 480.60
C₆-Ceramide	HCAEC	7933.4 ± 59.5	*17.09* ± 2.67	*680.26* ± 36.85

HCAEC bolded, italicized values differ significantly (p<0.05) compared to HCASMC with respective treatment, n = 9–10 separate replicate experiments.